The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Vasculo-immune modulatory effects of anti-VEGF therapy in metastatic clear cell renal cell carcinoma: The A-PREDICT trial.
 
Lewis Au
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche/Genentech
 
Zayd Tippu
No Relationships to Disclose
 
Husayn Pallikonda
No Relationships to Disclose
 
Anne-Laure Cattin
No Relationships to Disclose
 
Georgia Whitton
No Relationships to Disclose
 
Andrew Rowan
No Relationships to Disclose
 
Annika Fendler
No Relationships to Disclose
 
Jahangeer Malik
Honoraria - Astellas Pharma; AstraZeneca; Eisai; IPSEN; Merck
 
Ekaterini Boleti
No Relationships to Disclose
 
Naveen Vasudev
No Relationships to Disclose
 
Martin Highley
No Relationships to Disclose
 
Agnieszka Michael
Consulting or Advisory Role - Bristol-Myers Squibb; EUSA Pharma; GlaxoSmithKline; Ipsen; MSD
Research Funding - Ipsen
 
Tim Eisen
No Relationships to Disclose
 
Steven Penegar
No Relationships to Disclose
 
Rebecca Lewis
Research Funding - Roche (Inst)
 
Lucy Kilburn
No Relationships to Disclose
 
Judith Bliss
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); GlaxoSmithKline/Novartis (Inst); Janssen-Cilag (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Charles Swanton
Stock and Other Ownership Interests - Achilles Therapeutics; Bicycle Therapeutics; Epic Sciences; Relay Therapeutics
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Illumina; MSD; Novartis; Pfizer
Consulting or Advisory Role - Achilles Therapeutics; Bicycle Therapeutics; GRAIL; Medixci; Relay Therapeutics; Roche China; Saga Diagnostics; Sarah Cannon Research Institute
Research Funding - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Invitae; Ono Pharmaceutical; Personalis; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - PCT/EP2022/0779877 - Methods and systems for tumour monitoring; PCT/EP2023 - Analysis of HLA alleles transcriptional deregulation
Other Relationship - Chief Investigator for AZ MeRmaiD 1 and 2 clinical trials and Steering Committee Chair; Co-chief investgator of the NHS Galleri trial funded by GRAIL.
 
James Larkin
Honoraria - Bristol-Myers Squibb; Cancer Research UK; Eisai; GlaxoSmithKline; Gynavax; Incyte; iOnctura; Merck Serono; Novartis; Pfizer; Roche; touchEXPERTS; touchIME
Consulting or Advisory Role - Apple Tree Partners; Boston Biomedical; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Immunocore; Incyte; iOnctura; Iovance Biotherapeutics; Ipsen; Merck Serono; Novartis; Pfizer; Roche; YKT Corporation
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Roche; ESMO; GlaxoSmithKline; Roche/Genentech
 
Samra Turajlic
Speakers' Bureau - AstraZeneca; Idea Pharma; Merck; MSD; Novartis and Ipsen; Roche; Ventana Medical Systems
Research Funding - Cancer Research UK (Inst); Melanoma Research Alliance (MRA) (Inst); NIHR Biomedical Research Centre (Inst); roche (Inst); The Francis Crick Institute (Inst); the National Institute of Health (Inst); The Rosetrees Trust (Inst); The Royal Marsden Cancer Charity (Inst); UK Medical Research Council (Inst); Ventana Medical Systems (Inst); Wellcome Trust (Inst)
Patents, Royalties, Other Intellectual Property - patent on indels as a biomarkeer (Inst)